Aurobindo snaps up US businesses from Sandoz

Aurobindo is set to become the second largest generics player in the US by number of prescriptions, and the second largest dermatology player in the US, after agreeing to acquire Sandoz’ dermatology and oral solids businesses inadeal worth US$1.0 billion.